FY2017 EPS Estimates for uniQure N.V. Raised by Leerink Swann (QURE)
uniQure N.V. (NASDAQ:QURE) – Equities research analysts at Leerink Swann raised their FY2017 earnings per share estimates for uniQure N.V. in a research report issued on Tuesday. Leerink Swann analyst J. Schwartz now anticipates that the biotechnology company will earn ($2.94) per share for the year, up from their prior forecast of ($3.01). Leerink Swann also issued estimates for uniQure N.V.’s Q4 2017 earnings at ($0.88) EPS, FY2018 earnings at ($2.73) EPS, FY2019 earnings at ($2.79) EPS and FY2020 earnings at ($3.56) EPS.
uniQure N.V. (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.05). uniQure N.V. had a negative net margin of 338.39% and a negative return on equity of 170.28%. The company had revenue of $4.94 million during the quarter, compared to analysts’ expectations of $2.92 million.
QURE has been the topic of several other reports. ValuEngine upgraded uniQure N.V. from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research downgraded uniQure N.V. from a “buy” rating to a “hold” rating in a research note on Friday. Evercore ISI began coverage on uniQure N.V. in a research note on Tuesday. They set an “outperform” rating and a $22.00 target price on the stock. Finally, Chardan Capital set a $13.00 target price on uniQure N.V. and gave the stock a “buy” rating in a research note on Sunday, July 23rd. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $17.43.
uniQure N.V. (QURE) opened at $15.89 on Thursday. uniQure N.V. has a one year low of $4.72 and a one year high of $21.35. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 3.64.
Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC lifted its position in uniQure N.V. by 27.5% during the 1st quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock worth $8,661,000 after acquiring an additional 323,345 shares during the period. JPMorgan Chase & Co. lifted its position in uniQure N.V. by 33.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock worth $362,000 after acquiring an additional 14,659 shares during the period. Morgan Stanley lifted its position in uniQure N.V. by 14.9% during the 1st quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock worth $3,271,000 after acquiring an additional 73,418 shares during the period. Paloma Partners Management Co lifted its position in uniQure N.V. by 717.7% during the 1st quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock worth $491,000 after acquiring an additional 74,605 shares during the period. Finally, Mangrove Partners acquired a new stake in uniQure N.V. during the 2nd quarter worth about $247,000. 29.95% of the stock is owned by institutional investors.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.